[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital Sestre Milosrdnice\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":133},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,74,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100592161","impact-of-ded-on-the-accuracy-of-preoperative-keratometry-values-in-the-calculation-of-iol-power-for-cataract-surgery-100592161",false,"NCT06989827","Impact of DED on the Accuracy of Preoperative Keratometry Values in the Calculation of IOL Power for Cataract Surgery.","Evaluation of the Influence of Dry Eye Disease on the Precision of Preoperative Keratometry Measurements and Its Effect on Intraocular Lens Power Calculations in Patients Undergoing Cataract Surgery.","Inclusion Criteria:\n\n* healthy controls scheduled to undergo cataract surgery\n* patients diagnosed with dry eye disease scheduled to undergo cataract surgery\n\nExclusion Criteria:\n\n* patients already on therapy regimen using Preservative free artificial tears\n* patients on antihistamines\u002Fdecongestants, antidepressants, anti-Parkinson's, antipsychotics and antispasmodic medications.",true,"ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study looks at how dry eye disease can affect important eye measurements needed before cataract surgery. These measurements guide us in choosing the right artificial lens to implant, which is essential for achieving clear vision after the procedure. We are currently investigating whether patients with dry eyes tend to have less reliable readings due to surface irregularities on the eye. Our goal is to better understand this connection so we can improve pre-surgical preparation for patients with dry eye and help ensure better visual outcomes after cataract surgery.",[27,28],"Dry Eye Disease (DED)","Cataract",[30,31,32,33,34,35],"keratometry","IOL","intraocular lens","cataract surgery","dry eye disease","DED","NOT_YET_RECRUITING","2025-05-22",{"date":39,"type":40},"2025-05-25","ACTUAL",{"date":42,"type":21},"2025-06-02",{"date":44,"type":21},"2026-03",{"name":46,"class":47},"University Hospital Sestre Milosrdnice","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":48},"100589528","efficacy-of-lipid-containing-artificial-tears-in-the-treatment-of-dry-eye-100589528","NCT06955585","Efficacy of Lipid-containing Artificial Tears in the Treatment of Dry Eye","Inclusion Criteria:\n\n* Ocular Surface Disease Index (OSDI) score between 14 and 50 and at least one positive diagnostic test: tear break-up time (TBUT) \\\u003C7 seconds, Schirmer I test (≤10 mm\u002F5 min), or positive corneal staining based on the Oxford grading scheme. In addition, participants must not have used artificial tears for at least two weeks prior to enrollment, even if they were previously on such therapy\n\nExclusion Criteria:\n\n* use of systemic or topical corticosteroids, active ocular infection, or ocular surgery within the last 3 months",{"count":56,"type":21},50,[24],"This clinical study involves patients with Dry Eye Disease (DED) who are visiting an ophthalmology outpatient clinic. Eligible participants must have an Ocular Surface Disease Index (OSDI) score ≥14 and \\\u003C50, and at least one positive diagnostic test: tear break-up time (TBUT) \\\u003C7 seconds, Schirmer I test \\\u003C10 mm\u002F5 min, or positive corneal staining based on the Oxford grading scale. At baseline, tear film thickness will be measured using Pentacam imaging. Participants will then receive Proluxx eye spray, applied four times daily for 28 days. After this treatment period, a follow-up examination with all baseline assessments will be repeated.",[60,61,62],"Dry Eye Disease","Dry Eye","Dry Eye, Evaporative",[64,65],"dry eye","artificial tears","2025-04-24",{"date":68,"type":40},"2025-05-02",{"date":70,"type":21},"2025-04-25",{"date":72,"type":21},"2025-09",{"name":46,"class":47},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":4},"100553733","early-phase-1-cerebrolysin-as-an-add-on-therapy-to-standard-treatment-of-basilar-artery-occlusion-100553733","NCT06489925","Cerebrolysin as an Add-On Therapy to Standard Treatment of Basilar Artery Occlusion","Cerebrolysin as an Add-On Therapy to Standard Treatment of Posterior Circulation Stroke Secondary to Basilar Artery Occlusion","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Acute basilar artery occlusion confirmed on MSCT\u002F MR angiography\n* Premorbid mRS ≤ 3\n* Signed written consent\n\nExclusion Criteria:\n\n* Hypersensitivity to one of the components of the drug\n* Breastfeeding and pregnancy\n* Epilepsy, epileptic seizure\n* Severe renal impairment (grade IV and V)\n* Ischemic stroke in the previous three months\n* Metastatic cancer\n* Sepsis or a severe infection on admission\n* Acute coronary syndrome, pulmonary embolism, and deep venous thrombosis on admission",{"count":82,"type":21},20,[84],"EARLY_PHASE1","The standard therapy for acute ischemic posterior circulation stroke (PCS) often leads to poor functional outcomes and high mortality rates, despite all advances in reperfusion therapy. Recent trials have shown that adding Cerebrolysin, a cerebral neuroprotective agent, to standard therapy for patients with acute ischemic anterior circulation stroke is safe and leads to improved functional outcomes. The purpose of this study is to assess the effectiveness and safety of Cerebrolysin with standard treatment for patients with PCS secondary to basilar artery occlusion (BAO).\n\nThe plan is to conduct a prospective, single-center, single-arm, open-label study with 20 acute basilar artery occlusion patients and premorbid modified Rankin Score (mRS) ≤3, treated with standard treatment (mechanical thrombectomy ± intravenous alteplase or conservative treatment) and Cerebrolysin as add-on therapy, compared with historical controls. Besides standard acute stroke assessment, standard treatment, and rehabilitation, the participants who meet the eligibility criteria will receive Cerebrolysin in a single-day dosage of 30 ml intravenously for 14 consecutive days. The participants will be closely monitored, and neuroimaging findings and clinical outcomes will be obtained during the drug administration period, on discharge, one month, and 3 months after the treatment onset.\n\nThe primary endpoints are mRS (0-3) on day 90 and mortality rate 90 days after the stroke onset. The secondary endpoints are defined as a change in any type of intracerebral bleeding and a change of min. 2 points on the National Institutes of Health Stroke Scale 24 hours, 14 days, 30 days, and 90 days post-stroke.\n\nThe investigators hypothesize that adding Cerebrolysin to standard stroke treatment will improve clinical outcomes and reduce morbidity and mortality in patients with acute basilar occlusion compared to standard treatment alone.",[87,88],"Basilar Artery Occlusion","Posterior Circulation Brain Infarction",[90,91,92,93,94],"Cerebrolysin","neuroprotection","basilar artery occlusion","add-on therapy","posterior circulation stroke","2024-07-08",{"date":97,"type":40},"2024-07-09",{"date":99,"type":21},"2024-07",{"date":101,"type":21},"2026-05",{"name":46,"class":47},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":112,"conditions":113,"keywords":118,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100545635","the-impact-of-rhinoplasty-approach-and-used-autologous-cartilage-grafts-on-the-nasal-skin-soft-tissue-envelope-metabolism-100545635","NCT06384469","The Impact of Rhinoplasty Approach and Used Autologous Cartilage Grafts on the Nasal Skin-soft Tissue Envelope Metabolism","Inclusion Criteria:\n\n* Adult patients undergoing primary functional rhinoplasty who comply with the study\n* Adult patients undergoing primary functional rhinoplasty who have singed the informed consent, previously approved by the ethics commitee.\n\nExclusion Criteria: -\n\n* patients with previous surgical procedures to the nose\n* patients with greater previous injury or burns to the nasal skin\n* patients with autoimmune skin conditions\n* patients with significant cardiovascular diseases\n* patients unwilling to comply with the study\n* patients who do not want to sign the informed consent, previously approved by the ethics commitee.","80 Years",{"count":20,"type":21},"OBSERVATIONAL","This is a prospective observation cohort investigation. Patients, that is participants, undergoing primary functional rhinoplasty will be evaluated in terms of measuring capillary blood lactic acid concentration in the nasal skin-soft tissue envelope immediately after the procedure and 7 days after the procedure.\n\nThe aim of our study is to test whether or not different rhinoplasty approaches and volume of the used autologous cartilage grafts impact the nasal skin-soft tissue metabolism.",[114,115,116,117],"Rhinoplasty","Nasal Skin-soft Tissue Envelope Metabolism","Lactic Acid","Autologous Cartilage Grafting",[119,120,121,122,123,124],"Open rhinoplasty approach","Closed rhinoplasty approach","Lactic acid","Skin-soft tissue envelope","Metabolism","Autologous cartilage grafting","2024-04-25",{"date":127,"type":40},"2024-04-29",{"date":129,"type":21},"2025-01-02",{"date":131,"type":21},"2026-09-01",{"name":46,"class":47},""]